Bullish Moving Averages
5
Bearish Moving Averages
11
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
99.60Today’s High
103.2052W low
80.0052W High
132.40Open Price
102.00Prev. Close
96.2500Volume
12173.00Value
1223386.50Fundamentals
Market Cap Cr
158.80
Price to Earnings
45.10
Price to Book Value
2.50
Dividend Yield
1.00
PE to Growth
4.10
Op Revenue TTM Cr
327.04
Net Profit TTM Cr
3.52
Cash From Operating Activity Cr
-1.84
Return on Equity %
4.03
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
03 May, 2024
76.8
Week
65.4
Month
64.5
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
101.10
PIVOT
First Resistance
102.60
Second Resistance
104.70
Third Resistance
106.20
First Support
99.00
Second Support
97.50
Third Support
95.40
Relative Strength Index
49.29
Money Flow Index
61.15
MACD
-0.48
MACD Signal
-0.92
Average True Range
4.3
Average Directional Index
18.65
Rate of Change (21)
3.82
Rate of Change (125)
16.72
Commodity Channel Index
10.2
Williams %R
-55.8
BETA
1 Month
0.53
3 Month
1.46
1 Year
0.58
3 Year
0.23
PRICE CHANGE ANALYSIS
↑ 0.2%
1 Week
Low
High
98.5
106
↓ -1.95%
1 Month
Low
High
96.15
106
↓ -20.33%
3 Months
Low
High
88.95
129.9
↑ 8.3%
6 Months
Low
High
88.95
132.45
↑ 19.08%
1 Year
Low
High
80
132.45
| Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 81.75 | 92.71 | 70.61 | 82.41 | 77.34 | 75.44 | 70.07 | 77.70 | 70.10 | 67.91 | 71.14 | |
| Operating Expenses Qtr | 73.87 | 84.65 | 63.32 | 73.70 | 70.26 | 69.04 | 64.07 | 70.28 | 62.89 | 60.60 | 63.52 | |
| Operating Profit Qtr | 7.63 | 7.65 | 6.84 | 8.27 | 6.30 | 6.01 | 5.44 | 3.48 | 6.10 | 6.41 | 7.10 | |
| EBIDT Qtr Cr | 7.89 | 8.07 | 7.29 | 8.71 | 7.08 | 6.39 | 6.00 | 7.42 | 7.21 | 7.32 | 7.62 | |
| Depreciation Qtr | 2.55 | 2.02 | 2.12 | 1.66 | 2.03 | 1.96 | 1.83 | 2.11 | 1.71 | 1.72 | 1.69 | |
| Net Profit Qtr | 1.26 | 1.60 | 1.20 | 2.12 | 1.47 | 1.13 | 1.41 | 2.77 | 1.22 | 3.05 | 2.15 | |
| Basic EPS Qtr | 0.80 | 1.02 | 0.76 | 1.35 | 0.94 | 0.72 | 0.95 | 1.87 | 0.82 | 2.06 | 1.45 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 305.25 | 286.86 | 252.00 | 174.29 | 225.83 | |
| Operating Expenses Annual Cr | 277.07 | 257.16 | 222.99 | 163.92 | 202.77 | |
| Operating Profit Annual | 26.03 | 23.20 | 26.32 | 6.75 | 20.31 | |
| Operating Profit Margin Annual % | 8.53 | 8.09 | 10.44 | 3.87 | 8.99 | |
| Total Expenses Annual Cr | 296.70 | 274.80 | 242.20 | 183.36 | 221.41 | |
| EBIDT Annual Cr | 28.19 | 29.69 | 29.01 | 10.37 | 23.05 | |
| EBIDT Annual margin % | 9.23 | 10.35 | 11.51 | 5.95 | 10.21 | |
| Depreciation | 7.48 | 7.24 | 7.26 | 7.03 | 6.12 | |
| PAT Before ExtraOrdinary Items Annual Cr | 6.13 | 8.58 | 9.10 | -8.90 | 6.76 | |
| Net Profit Annual | 6.13 | 8.58 | 9.10 | -8.90 | 6.76 | |
| Basic EPS Annual | 3.90 | 5.79 | 6.41 | -6.28 | 4.77 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 96.03 | 87.32 | 79.32 | 65.94 | 76.86 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 39.52 | 37.72 | 35.35 | 33.42 | 37.24 | |
| Total Current Liabilities Annual Cr | 212.15 | 164.57 | 146.87 | 139.95 | 143.05 | |
| Total Capital Plus Liabilities Annual Cr | 347.70 | 289.61 | 261.54 | 239.31 | 257.15 | |
| Fixed Assets Annual | 63.07 | 54.06 | 52.65 | 56.24 | 57.00 | |
| Total Non Current Assets Annual | 77.75 | 69.35 | 68.34 | 66.84 | 69.79 | |
| Total Current Assets Annual | 269.95 | 220.27 | 193.20 | 172.47 | 187.37 | |
| Total Assets Annual | 347.70 | 289.61 | 261.54 | 239.31 | 257.15 | |
| Contingent Liabilities plus Commitments Annual Cr | 16.44 | 16.25 | 4.34 | 12.99 | 20.37 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 5.07 | 31.48 | 10.24 | 21.57 | 9.10 | |
| Cash from Investing Activity Annual | -22.08 | -13.43 | -6.66 | -3.16 | -9.53 | |
| Cash from Financing Annual Activity | 17.43 | -18.13 | -3.36 | -19.94 | 0.05 | |
| Net Cash Flow Annual | 0.42 | -0.08 | 0.22 | -1.52 | -0.38 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 61.21 | 58.91 | 53.51 | 46.53 | 54.23 | |
| ROE Annual % | 6.37 | 9.82 | 11.46 | -13.49 | 8.79 | |
| ROCE Annual % | 15.27 | 17.95 | 18.97 | 3.36 | 14.84 | |
| Total Debt to Total Equity Annual | 1.30 | 1.12 | 1.25 | 1.42 | 1.26 | |
| EBDIT Annual Margin % | 9.29 | 10.59 | 11.63 | 6.07 | 10.33 |
| Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 81.76 | 92.68 | 70.54 | 82.64 | 77.08 | 75.36 | 70.08 | 77.75 | 69.92 | 67.73 | 70.96 | |
| Operating Expenses Qtr | 73.87 | 84.85 | 63.94 | 74.29 | 70.47 | 69.53 | 64.81 | 70.60 | 62.95 | 60.85 | 63.34 | |
| Operating Profit Qtr | 7.79 | 7.70 | 6.44 | 8.16 | 6.15 | 5.77 | 5.03 | 3.45 | 6.22 | 6.33 | 7.49 | |
| EBIDT Qtr Cr | 7.89 | 7.84 | 6.60 | 8.35 | 6.61 | 5.82 | 5.28 | 7.15 | 6.97 | 6.88 | 7.62 | |
| Depreciation Qtr | 2.96 | 2.42 | 2.53 | 2.09 | 2.45 | 2.37 | 2.23 | 2.42 | 2.21 | 2.21 | 2.19 | |
| Net Profit Qtr | 0.89 | 0.95 | 0.08 | 1.60 | 0.57 | 0.13 | 0.28 | 2.19 | 0.64 | 1.38 | 1.62 | |
| Basic EPS Qtr | 0.54 | 0.62 | 0.06 | 1.03 | 0.38 | 0.07 | 0.19 | 1.33 | 0.32 | 0.97 | 1.14 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 305.16 | 286.37 | 251.67 | 172.93 | 226.02 | |
| Operating Expenses Annual Cr | 279.09 | 257.74 | 226.07 | 166.33 | 207.50 | |
| Operating Profit Annual | 25.12 | 23.48 | 24.46 | 4.76 | 17.51 | |
| Operating Profit Margin Annual % | 8.23 | 8.20 | 9.72 | 2.75 | 7.75 | |
| Total Expenses Annual Cr | 300.41 | 277.18 | 247.56 | 186.46 | 226.22 | |
| EBIDT Annual Cr | 26.06 | 28.63 | 25.60 | 6.60 | 18.52 | |
| EBIDT Annual margin % | 8.54 | 10.00 | 10.17 | 3.82 | 8.19 | |
| Depreciation | 9.13 | 9.04 | 9.52 | 7.68 | 6.16 | |
| PAT Before ExtraOrdinary Items Annual Cr | 2.62 | 5.70 | 4.71 | -12.89 | 2.15 | |
| Net Profit Annual | 2.57 | 5.61 | 4.74 | -12.22 | 3.79 | |
| Basic EPS Annual | 1.67 | 3.79 | 3.34 | -9.10 | 1.52 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 63.79 | 58.63 | 53.58 | 52.43 | 66.64 | |
| Minority Interest Liability Annual Cr | -0.09 | -0.13 | -0.23 | -7.09 | -6.42 | |
| Total Non Current Liabilities Annual Cr | 40.14 | 36.40 | 34.19 | 33.56 | 37.85 | |
| Total Current Liabilities Annual Cr | 209.33 | 165.64 | 152.53 | 159.49 | 163.24 | |
| Total Capital Plus Liabilities Annual Cr | 313.17 | 260.53 | 240.08 | 238.39 | 261.31 | |
| Fixed Assets Annual | 72.64 | 65.18 | 64.76 | 70.20 | 70.19 | |
| Total Non Current Assets Annual | 85.02 | 75.96 | 75.93 | 77.26 | 79.40 | |
| Total Current Assets Annual | 228.16 | 184.57 | 164.15 | 161.14 | 181.91 | |
| Total Assets Annual | 313.17 | 260.53 | 240.08 | 238.39 | 261.31 | |
| Contingent Liabilities plus Commitments Annual Cr | 0.00 | 0.00 | 4.34 | 12.99 | 20.37 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -1.84 | 27.71 | 21.78 | 23.10 | 7.76 | |
| Cash from Investing Activity Annual | -22.18 | -9.48 | -4.98 | -4.71 | -8.04 | |
| Cash from Financing Annual Activity | 24.40 | -18.13 | -16.63 | -19.97 | 0.01 | |
| Net Cash Flow Annual | 0.37 | 0.09 | 0.17 | -1.58 | -0.27 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 40.60 | 39.46 | 35.99 | 31.99 | 42.49 | |
| ROE Annual % | 4.03 | 9.57 | 8.85 | -23.30 | 5.68 | |
| ROCE Annual % | 16.30 | 20.64 | 18.36 | -1.36 | 12.60 | |
| Total Debt to Total Equity Annual | 2.05 | 1.67 | 1.95 | 2.15 | 1.74 | |
| EBDIT Annual Margin % | 8.56 | 10.18 | 10.21 | 3.85 | 8.22 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| SHAILESH SIROYA | 17.37 | 74518015 | 0 | 50.99 |
| ANITA SIROYA | 6.64 | 74518016 | 0 | 0 |
| ANAND SURANA | 3.33 | 74518017 | 0 | 0 |
| DILIP SURANA | 3.01 | 74518018 | 0 | 0 |
| ARCHANA SURANA | 1.8 | 74518019 | 0 | 0 |
| MONICA SURANA | 1.14 | 74518020 | 0 | 0 |
| DILIP SURANA (HUF) | 1.08 | 74518021 | 0 | 0 |
| MICRO LABS | 12.73 | 74518024 | 0 | 0 |
| CHANDRAPRAKASH DHEERAJMAL SIROYA | 3.08 | 74518026 | 0 | 0 |
| ANNITA CHANDRAPRAKASH SIROYA | 0.78 | 74518027 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|
| Name | Holding Percent | Holding Id |
|---|---|---|
| Naresh D.P | 1.9 | 74518038 |
| Shreya Mardia | 1.9 | 74518039 |
| HUF | 2.51 | 74518032 |
| Prakash Chandra Jain | 3.68 | 74518041 |
| Ram Keshav Murthy | 3.65 | 74518042 |
| Asha Tapidas Dodhia | 1.86 | 74518043 |
| Gautam Chand Mehta | 1.29 | 74518044 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Sep 18, 2023 | 1 | FINAL | - | Equity Share |
| Sep 13, 2022 | 1 | FINAL | - | Equity Share |
| Sep 16, 2021 | 1 | FINAL | - | Equity Share |
| Sep 17, 2019 | 1 | FINAL | - | Equity Share |
| Sep 14, 2018 | 1 | FINAL | - | Equity Share |
| Sep 14, 2017 | 1 | FINAL | - | Equity Share |
| Sep 15, 2016 | 1 | FINAL | - | Equity Share |
| Sep 15, 2015 | 1 | FINAL | - | Equity Share |
| Sep 12, 2014 | 1 | FINAL | - | Equity Share |
| Sep 12, 2013 | 0.75 | FINAL | - | Equity Share |
| Sep 17, 2009 | 0.75 | FINAL | - | Equity Share |
| Sep 09, 2008 | 1 | FINAL | - | Equity Share |
| Sep 07, 2007 | 0.75 | FINAL | - | Equity Share |
| Sep 07, 2006 | 0.75 | FINAL | - | Equity Share |
| Sep 09, 2005 | 0.75 | FINAL | - | Equity Share |
| Sep 01, 2004 | 1.5 | FINAL | - | Equity Share |
| Sep 11, 2002 | - | FINAL | - | Equity Share |
| Sep 03, 2001 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 28, 2024 | Audited Results & Final Dividend | - |
| Feb 12, 2024 | Quarterly Results | - |
| Nov 08, 2023 | Quarterly Results & ESOP | - |
| Aug 11, 2023 | Quarterly Results & A.G.M. | - |
| May 29, 2023 | Audited Results & Final Dividend | - |
| Feb 06, 2023 | Quarterly Results | - |
| Nov 14, 2022 | Quarterly Results & ESOP | Inter alia, To convene Extra Ordinary General Meeting ( EGM ) for merger of Golden Drugs Pvt Ltd. a wholly owned subsidiary of the Company. |
| Aug 11, 2022 | Quarterly Results | - |
| May 30, 2022 | Audited Results & Final Dividend | - |
| Apr 13, 2022 | Preferential issue of shares | - |
| Mar 09, 2022 | Scheme of Amalgamation | Inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd. |
| Feb 10, 2022 | Quarterly Results | - |
| Nov 11, 2021 | Quarterly Results | - |
| Aug 10, 2021 | Quarterly Results | - |
| Jun 29, 2021 | Audited Results & Final Dividend | - |
| Mar 17, 2021 | Preferential Issue of shares | Inter alia, to consider and approve allotment of equity shares to the beneficiaries who have exercised the conversion option on the warrants allotted to them on preferential basis. |
| Feb 11, 2021 | Quarterly Results & Others | - |
| Nov 11, 2020 | Quarterly Results | - |
| Oct 28, 2020 | To consider issue of Warrants | To consider allotment of 14,00,000 warrants to Mr.Shailesh Siroya, promoter of the Company on preferential basis. |
| Sep 08, 2020 | Quarterly Results | - |
| Jul 29, 2020 | Audited Results & A.G.M. | - |
| Jun 29, 2020 | Audited Results | - |
| Feb 12, 2020 | Quarterly Results | - |
| Nov 14, 2019 | Quarterly Results | - |
| Aug 13, 2019 | Quarterly Results | (Revised) |
| Aug 08, 2019 | Quarterly Results | - |
| May 30, 2019 | Audited Results & Final Dividend | (Revised) |
| May 29, 2019 | Audited Results & Final Dividend | - |
| Feb 13, 2019 | Quarterly Results | - |
| Nov 14, 2018 | Quarterly Results | - |
| Aug 10, 2018 | Quarterly Results | - |
| May 29, 2018 | Audited Results & Dividend | - |
| Feb 14, 2018 | Quarterly Results | - |
| Dec 11, 2017 | Quarterly Results | - |
| Sep 11, 2017 | Quarterly Results | - |
| Aug 10, 2017 | Others | To approve the 30th Annual General Meeting Notice (AGM), Directors Report and Corporate Governance reports of the Company, for the financial year ended 31.03.2017. |
| May 30, 2017 | Audited Results & Dividend | - |
| Feb 07, 2017 | Quarterly Results | - |
| Nov 14, 2016 | Quarterly Results | - |
| Aug 10, 2016 | Quarterly Results | To consider certain key business propositions. |
| May 25, 2016 | Audited Results & Dividend | - |
| Apr 13, 2016 | Allotment of Equity Shares | - |
| Feb 10, 2016 | Quarterly Results | - |
| Nov 09, 2015 | Quarterly Results | - |
| Aug 13, 2015 | Quarterly Results | Appointed Mr. Sanjay Kumar Agarwal as Company Secretary and Compliance officer of the Company. |
| May 29, 2015 | Audited Results & Dividend | - |
| Mar 27, 2015 | Others | Appointed Ms.Sarika Bhandari as additional Director on the Board of the Company. |
| Feb 12, 2015 | Quarterly Results | - |
| Nov 08, 2014 | Quarterly Results | - |
| Oct 20, 2014 | Others | To consider issue and allotment of warrants to the investors on preferential basis. |
| Aug 11, 2014 | Quarterly Results & Others | Preferential Issue of shares |
| May 28, 2014 | Audited Results & Dividend | - |
| Feb 12, 2014 | Quarterly Results | - |
| Nov 13, 2013 | Quarterly Results | - |
| Aug 12, 2013 | Quarterly Results | - |
| May 27, 2013 | Audited Results & Dividend | - |
| Feb 12, 2013 | Quarterly Results | - |
| Nov 09, 2012 | Quarterly Results | - |
| Aug 10, 2012 | Audited & Quarterly Results | 1. Propose issue and allotment of warrants on preferential basis to the promoters and to strategic investors. 2. Approve the audited accounts of the Company for the F.Y. ended March 31, 2012. |
| May 10, 2012 | Quarterly Results | - |
| Feb 03, 2012 | Quarterly Results | - |
| Nov 08, 2011 | Quarterly Results | - |
| Aug 10, 2011 | Audited & Quarterly Results | - |
| May 15, 2011 | Quarterly Results | (Revised) |
| Jan 31, 2011 | Quarterly Results | - |
| Nov 13, 2010 | Quarterly Results | - |
| Aug 06, 2010 | Audited & Quarterly Results | - |
| May 14, 2010 | Quarterly Results | - |
| Jan 27, 2010 | Quarterly Results | - |
| Oct 31, 2009 | Quarterly Results | - |
| Jul 27, 2009 | Quarterly Results | - |
| Jun 29, 2009 | Audited Results & Dividend | - |
| May 28, 2009 | Scheme of Amalgamation | To consider & approve the draft Scheme of Amalgamation of Basav Chem Ltd. (100% subsidiary Company) , with the Company in terms of Sections 391 to 394 of the Companies Act, 1956. |
| Jan 30, 2009 | Quarterly Results | - |
| Oct 27, 2008 | Quarterly Results & Others | To allot 37,000 equity shares of face value @ Rs 10/- each, allotted at Rs 15.75/- per equity share to the eligible employees of the Company under ESOP Scheme, 2006. |
| Jul 30, 2008 | Quarterly Results | - |
| Jun 23, 2008 | Audited Results & Dividend | - |
| Apr 16, 2008 | Others | Inter alia, to take on record the sales performance of the Company, up to March 31, 2008. |
| Jan 24, 2008 | Quarterly Results | - |
| Oct 30, 2007 | Quarterly Results | - |
| Jul 30, 2007 | Quarterly Results | - |
| Jun 30, 2007 | Audited Results | - |
| Jan 31, 2007 | Quarterly Results | - |
| Oct 27, 2006 | Quarterly Results | - |
| Jul 31, 2006 | Quarterly Results | - |
| Jun 30, 2006 | Accounts | - |
| Apr 30, 2006 | Quarterly Results | - |
| Jan 30, 2006 | Quarterly Results | - |
| Oct 29, 2005 | Quarterly Results | - |
| Jul 30, 2005 | Quarterly Results | - |
| Jun 30, 2005 | Accounts & Dividend | - |
| May 31, 2005 | Others | To review of the response of the shareholders with regard to Right Issue |
| Jan 31, 2005 | Quarterly Results | - |
| Dec 26, 2004 | Right Issue of Equity Shares | & To obtain share holders approval by postal ballot to amend object clause of the MOA. |
| Oct 31, 2004 | Quarterly Results | - |
| Oct 07, 2004 | Preferential Issue of shares | 1) Allotment of 10,30,000 shares on preferential basis and 2) Redemption of preference shares. |
| Jul 31, 2004 | Others | Approved allotment of Equity shares on Preferential basis |
| Apr 30, 2004 | Quarterly Results | - |
| Jan 30, 2004 | Quarterly Results | - |
| Oct 23, 2003 | Quarterly Results | - |
| Jul 28, 2003 | Quarterly Results | (Revised) |
| Jul 14, 2003 | Accounts & Dividend | - |
| Apr 26, 2003 | Quarterly Results | - |
| Jan 30, 2003 | Quarterly Results | (Revised) |
| Oct 29, 2002 | Quarterly Results | - |
| Jul 15, 2002 | Accounts, Dividend & Quarterly Results | - |
| Apr 30, 2002 | Quarterly Results | - |
| Jan 30, 2002 | Quarterly Results | - |
| Oct 31, 2001 | Quarterly Results | - |
| Jul 30, 2001 | Accounts & Quarterly Results | - |
| Jan 30, 2001 | Quarterly Results | - |
| Oct 28, 2000 | Quarterly Results | - |
| Jul 28, 2000 | Quarterly Results | - |
| Apr 28, 2000 | Quarterly Results | - |
| Jan 28, 2000 | Quarterly Results | - |
| Oct 27, 1999 | Quarterly Results | - |
| Jul 30, 1999 | Quarterly Results | - |
| Apr 29, 1999 | Quarterly Results | - |
| Mar 06, 1999 | Pvt. Placements | - |
| Jan 29, 1999 | Quarterly Results | - |
| Oct 26, 1998 | Quarterly Results | - |
| May 30, 1998 | Half Yearly Results | - |
| Nov 28, 1997 | Half Yearly Results. | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
03 May 2024
BAL PHARMA LTD. - 524824 - Corporate Action-Board to consider Dividend
Please refer to our intimation regarding Board Meeting dated 30.04.2024.
30 Apr 2024
BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Notice For The Board Meeting
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 ,inter alia, to consider and approve 1.Audited Standalone and Consolidated financial results for the quarter and financial year ended 31.03.2024. 2.Audited standalone and consolidated accounts of the Company together with Directors and Auditors reports. 3. Recommendation of Dividend, if any, for the financial year ended 31.03.2024. 4.Appoinment of Internal Auditors, Cost Auditors and Secretarial Auditors for f.y ended 31.03.2024.
18 Apr 2024
BAL PHARMA LTD. - 524824 - Disclosure Of Statement Of Deviation/Veriation
Disclosure of Deviation / variation in utilization of issue proceeds from the objects stated in the explanatory statement to the notice of the general meeting for the quarter ended 31.03.2024 is not applicable for our Company i.e Bal Pharma Limited , as the preferential issue proceeds has been fully utilized.
17 Apr 2024
BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange intimation received from our R&T agent i.e Link Intime India Private Ltd, Mumbai regarding loss of share certificate by one of our shareholder.
15 Apr 2024
BAL PHARMA LTD. - 524824 - Compliance With Regulation 40(9) Of SEBI(LODR) Regulations.
Compliance certificate as per Regulation 40(9) of SEBI(LODR) Regulations , for the financial year ended 31.03.2024.
05 Apr 2024
BAL PHARMA LTD. - 524824 - Disclosures As Per Regulation 31(4) Of SEBI(SAST) Regulations.
We are submitting to the exchange disclosures by our promoters as per Regulation 31(4) of SEBI(SAST) Regulations for the financial year ended 31.03.2024.
05 Apr 2024
BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Confirmation as per Regulation 74(5) of SEBI (DP) Regulations for the quarter ended 31.03.2024.
04 Apr 2024
BAL PHARMA LTD. - 524824 - Regulation 7(3) Certificate For The Financial Year Ended 31.03.2024.
Compliance certificate as per Regulation 7(3) of SEBI(LODR) Regulations,2015.
02 Apr 2024
BAL PHARMA LTD. - 524824 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBAL PHARMA LTD. 2CIN NO.L85110KA1987PLC008368 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 44.81 4Highest Credit Rating during the previous FY BBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ACUITE RATINGS & RESEARCH LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Abdul Basith Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Bharath Bhushan Designation: CFO EmailId: [email protected] Date: 02/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
22 Mar 2024
BAL PHARMA LTD. - 524824 - Closure of Trading Window
Pursuant to the Code of Conduct of the Company and as per the amended provisions of SEBI(Prohibition of Insider Trading) Regulations,2015, We wish to inform the exchanges that the trading window for dealing with the securities of the Company on the designated persons and their immediate relatives will be closed from 1st April 2024 and up to 48 hours of the declaration of the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2024. The date of the Board meeting for declaration of audited financial results will be intimated to the exchanges in due course.
